Sulbutiamine shows neuroprotective effects on hippocampal CA1 pyramidal neurons subjected to oxygen-glucose deprivation. Sulbutiamine enhances electrophysiological properties such as excitatory synaptic transmissions and intrinsic neuronal membrane input resistance in a concentration-dependent manner. Sulbutiamine attenuates apoptotic cell death induced by serum deprivation and stimulates GSH and GST activity in a dose dependent manner. Furthermore, sulbutiamine decreases the expression of cleaved caspase-3 and AIF.
| Cell Experiment | |
|---|---|
| Cell lines | neuroblastoma cells |
| Preparation method | Cell viability of hippocampal slices subjected to OGD with or without sulbutiamine was determined by TO-PRO-3 iodide staining (dilution 1 : 1000). |
| Concentrations | 1, 10 and 50 μM |
| Incubation time | 15 min |
| Animal Experiment | |
|---|---|
| Animal models | Rats |
| Formulation | Arabic gum, 15% w/v |
| Dosages | 12.5 mg/kg |
| Administration | i.p. |
| Molecular Weight | 702.89 |
| Formula | C32H46N8O6S2 |
| CAS Number | 3286-46-2 |
| Solubility (25°C) | 75 mg/mL in DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Products |
|---|
| OGT2115
OGT2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT2115 has anti-angiogenic properties (IC50 = 1 μM). |
| DiosMetin 7-O-β-D-Glucuronide
DiosMetin 7-O-β-D-Glucuronide is an antioxidant constituent in the fruits of Luffa cylindrical. |
| Bendazac L-Lysine
Bendazac L-Lysine is an aldose reductase (AR) inhibitor, which can be used to inhibit the activity of AR in the eye to prevent cataracts. |
| Ro5-3335
Ro5-3335 acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation. |
| Bendazac
Bendazac is an oxyacetic acid with anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties. Bendazac acts by preventing protein denaturation. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
